Yesterday, December 12, 2018, the Board issued Final Written Decisions finding Claims 1-25 of U.S. Patent No. 7,476,652 (IPR2017-01526) and Claims 1-20 of U.S. Patent No. 7,713,930 (IPR2017-01528) unpatentable as obvious over the prior art. IPR2017-01526 and IPR2017-01528 were two of a number of IPR petitions filed by Mylan against patents covering Sanofi’s Lantus® (insulin glargine) product, as we reported here. Sanofi has asserted the ‘652 and ‘930 patents against Mylan regarding their proposed follow-on insulin glargine product in the District of New Jersey (NJD-2-17-cv-09105-1). The parties have jointly requested an October 2019 trial date but the court has not yet set the trial date in this case.
The post PTAB Issues Final Written Decisions Finding Two Of Sanofi’s Lantus Patents Invalid appeared first on Big Molecule Watch.